

Hormonal IUS Access Group

April 2020: Updates for Key Stakeholders

Background

- In 2015, a global working group was established to evaluate the potential to expand access to the hormonal IUS in low-resource settings
- Building upon the leadership of this group and at the country level, a global consortium comprised of donors (including USAID, BMGF, DFID and UNFPA), governments, and partner organizations have begun exploring concrete opportunities to **sustainably increase access to** the hormonal IUS beyond pilot settings
- The work to sustainably increase access to the hormonal IUS involves parallel efforts to **ensure affordability, accessibility, and long-term supply security, support demand-side strategies** for cost-effective product introduction, and continuing to **implement a robust learning agenda**
- At the end of 2019, this consortium formalized its efforts by establishing a **focused and phased strategy** for broader introduction and scale-up of hormonal IUS
- In 2020, this consortium evolved into the newly formed **Hormonal IUS Access Group** and began planning for the execution of this strategy, aimed at facilitating broader access to hormonal IUS in LMICs

Executive Summary: Key updates



The Hormonal IUS Access Group has been convened to connect work across the supply and demand sides of the market, including the upcoming developments:




- On the **demand side**, effectively increasing access to hormonal IUS in LMICs will require the implementation of a **phased product introduction** approach, with a high degree of coordination across countries **to match scale-up of training and other introduction activities with available supply**, and to ensure countries that choose to introduce the method are prepared to do so efficiently



- On **the supply side**, UNFPA and USAID are in the process of **adding hormonal IUS to their product catalogs for procurement**

- Despite potential delays resulting from COVID-19, supply of the method is still expected to be available for donor procurement for the public sector in LMICs by the end of 2020



- **Product affordability is key** – once achieved, targeted donor funding will be available to support public sector product introduction efforts

- For example, DFID has set aside additional earmarked funding for countries to procure the hormonal IUS through UNFPA Supplies, ensuring commodity funding is not a barrier for countries wishing to introduce the product

Approach: Hormonal IUS Access Group evolved structure

**Note: This overall structure could be transitioned or updated as the global landscape evolves*

1

Steering Committee

Donor and procurer decision-making group tasked with developing and monitoring implementation of the overall global targeted, phased strategy to expand access to hormonal IUS and strengthen hormonal IUS market; identify and mitigate risks in market health; maintain relationships with suppliers; review demand forecasts; support CSP with prioritization as needed; disseminate regular communications.

Supplier Coordination Sub-Group

The Steering Committee will also organize biannual calls/meetings with **suppliers** to communicate relevant supply updates (i.e. production capacity), and to share progress/challenges related to product rollout

2

Partners Group

Partner and procurer technical working group supporting implementation of country programs’ targeted phased strategies, sharing of lessons learned across programs, and sharing information to inform steering committee decision-making.

Supplier Technical Exchange Sub-Group

The Partners Group will also organize ad-hoc calls/meetings with **suppliers**, where suppliers will be invited to share product-specific technical expertise to support partner implementation

The Steering Committee and Partners Group will work closely together to disseminate key information and ensure strategic coordination within broader FP community e.g. through new Method Choice COP

Roles and responsibilities in Hormonal IUS Access Group Steering Committee

1 Steering Committee	
2020 Membership	<p>Standing decision-making members: DFID, USAID, UNFPA, BMGF</p> <p>Standing supporting, non-decision-making members: GHSC-PSM, CHAI*, FHI 360*, CSP/GFPVAN**</p> <p>Suppliers (Bayer, Medicines360, Others-TBD) participate by invitation</p> <p>*Shared secretariat role for 2020: Secretariat responsibilities include conducting analysis and gathering documentation needed for decision-making, preparing and proposing agendas, capturing meeting minutes and next steps, and making recommendations as appropriate.</p> <p>**Sole purpose is to ensure holistic view of supply to facilitate donor/procurer decision-making at strategic level, especially as architecture is moving towards platform that is multiproduct</p>
2020 Meeting schedule	Bi-monthly; remote meetings, suggest that donors cost-share meetings or rotate hosting any in-person meetings
2020 Activities	<ul style="list-style-type: none"> Establish Hormonal IUS Access Group Develop and execute plan for communicating updates to hormonal IUS introduction landscape Achieve affordable pricing for the products; put in place strategy for long term supply security Ensure hormonal IUS products are added to UNFPA and USAID product catalogs Confirm 2020 DFID donor funding availability for commodity procurement; confirm for DFID and others for 2021 Confirm 2020 DFID donor funding availability for method introduction activities/TA; confirm for DFID and others for 2021 Support funding and/or dissemination of new practices or guidelines/recommendations on service delivery for the method Complete country readiness review/identify target countries Review and align on cross-country indicators to determine what needs to be tracked Monitor commodity forecast; support prioritization of orders as needed leveraging GFPVAN Ensure key information is disseminated to broader FP community including research results from pilot activities and updates about evolving landscape on supply- and demand-sides Develop/launch joint online resource hub Coordinate with suppliers via biannual meetings tacked on to existing Steering Committee meetings (remote or in-person) – Supplier Coordination Sub- Group <ul style="list-style-type: none"> Suppliers provide updates on status of product supply and manufacturing capacity Share relevant information on issues regarding implementation and service delivery Work to address any relevant bottlenecks related to supply and supply chain issues Work to address how to engage the private sector for this method (with understanding that the public sector introduction happens first, per the Steering Committee’s phased, focused strategy)


Roles and responsibilities in Hormonal IUS Access Group

Partners Group

Partners Group	
2020 Membership	<p>Standing members: UNFPA, GHSC-PSM, countries (1-2 country government representative to participate on rotating basis), Jhpiego, PSI, FHI 360*, CHAI*, Population Council, MSI, CSP, WCG, Pathfinder, IPPF, etc.</p> <p>Donors (participate as they wish): DFID, USAID, BMGF</p> <p>Suppliers (Bayer, Medicines360, Others-TBD) participate by invitation</p> <p>*Shared secretariat role for 2020</p>
2020 Meeting schedule	Monthly; remote meetings, and for any in-person meetings, voluntary participation unless donor funding is available
2020 Activities	<ul style="list-style-type: none"> • Support coordination on hormonal IUS introduction landscape with in-country governments/ partners including through country-specific COPS • Share information and elevate feedback via rotating country representatives; virtually distribute information to a wider group of country focal points and collate feedback for discussion in the Partners Group • Develop supporting materials for countries to enable roll-out; contribute to joint online resource hub • Support development of enabling environment in countries that want to introduce the product • Support country readiness review/identify target countries • Support phase 1 target countries in development of targeted, phased introduction strategies • Update global learning agenda and propose cross-country indicators; propose mechanism for tracking data • Support implementation research/studies to answer key learning questions as defined in learning agenda • Contribute inputs to commodity forecast • Coordinate with suppliers via ad hoc meetings tacked onto existing Partners Group meetings (i.e. individual supplier may join existing Partners Group call at invite of Partners Group to discuss technical learnings/insertion technique training guidance) – Supplier Technical Exchange Sub-Group: <ul style="list-style-type: none"> • Suppliers share technical expertise, learnings and how to incorporate best practices (in training, education, etc.) into country introduction resources and implementation

Approach: Deep dive on the phased, focused lens

- Given the need to build on best practices to enable effective and efficient introduction and scale-up, the proposed path forward is to utilize an **intentional, focused and phased approach** to introduce the hormonal IUS more broadly
- Ultimately, the platform created for this product will **support the broader the goal of a total market approach** for hormonal IUS introduction to be leveraged once adequate supply for the private sector is available
- In the near term, this will entail **introduction in a group of countries that is ready and willing** to incorporate hormonal IUS into the method mix in a targeted set of public sector service-delivery points in order to expand choice for women



Next steps

- Ongoing leadership from country Ministries of Health and partners, and engagement with the Hormonal IUS Access Group will be essential to successful, sustainable hormonal IUS introduction; next steps aim to foster that collaboration
- The Partners Group will support coordination between country and global stakeholders; convening the Partners Group to begin work on priority activities (including reviewing focus country criteria and updating the learning agenda) is a key next step
- For now, countries and/or partners that are interested in expanding access to the hormonal IUS to meet the needs of women and girls should reach out to Devon Cain at CHAI (dcain@clintonhealthaccess.org) or Kate Rademacher at FHI 360 (krademacher@fhi360.org)
- The Hormonal IUS Access Group is developing a website where research outcomes and resources will be readily available for Ministries of Health and partners to leverage in preparation for introduction



Any questions?

Appendix: Hormonal IUS Enabling Environment, illustrative list of conditions required for successful adoption of the method



Country

- 1. Eligible for procurement and product introduction funding
- 2. Appropriate regulatory framework in place (i.e. product registered, guidelines updated)
- 3. Costed introduction plan has been developed, with MOH engagement and buy-in
- 4. Integration of method into country procurement and programmatic budgets, tools and processes (i.e. LMIS, HMIS)
- 5. Order volume quantification complete and introduction resources mobilized



Donor

- 1. Commodity funding for procurement of new products, accessed based on validated introduction plan
- 2. Service delivery/demand generation investment



Supplier

- 1. Product registered
- 2. Production capacity to meet country demand
- 3. Access pricing